论文部分内容阅读
目的观察急性左心衰竭患者应用冻干重组人脑利钠肽治疗的临床疗效。方法选取2013年1月~2015年9月接收的急性左心衰竭患者70例。利用随机双盲法,将70例患者分成试验组与对照组。两组都予以基础治疗,试验组加用冻干重组人脑利钠肽,对照组加用硝普钠。观察两组疗效,比较相关治疗指标。结果试验组总有效率为97.14%,对照组为71.43%;试验组明显高于对照组。两组对比差异有统计学意义(P<0.05)。针对用药后心率、血压以及心功能指标的改善情况,试验组明显优于对照组。两组对比差异有统计学意义(P<0.05)。结论常规治疗急性左心衰竭患者时合理加用冻干重组人脑利钠肽,可增强疗效,有助于疾病的归转。
Objective To observe the clinical efficacy of freeze-dried recombinant human brain natriuretic peptide in patients with acute left heart failure. Methods Seventy patients with acute left heart failure who received from January 2013 to September 2015 were enrolled. 70 patients were divided into experimental group and control group by randomized double-blind method. Both groups were given basic treatment, the experimental group plus freeze-dried recombinant human brain natriuretic peptide, the control group with sodium nitroprusside. Observed the two groups of curative effect, compared with related treatment index. Results The total effective rate was 97.14% in the experimental group and 71.43% in the control group. The experimental group was significantly higher than the control group. The difference between the two groups was statistically significant (P <0.05). For the treatment of heart rate, blood pressure and cardiac function improvement, the experimental group was significantly better than the control group. The difference between the two groups was statistically significant (P <0.05). Conclusions Routine treatment of acute left heart failure patients with reasonable addition of freeze-dried recombinant human brain natriuretic peptide, can enhance the efficacy, contribute to the return of the disease.